Incyte gains rights to Macrogenics' PD-1 inhibitor
By Jennie Walters | Oct 27, 2017 | 9:42 PM GMT
MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012. MacroGenics retains rights to develop combinations that include the
Read the full 273 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury